AuroraSkin & Laser (Miami)

Comprehensive Investment Analysis

Executive Summary

This comprehensive analysis of AuroraSkin & Laser (Miami) presents a detailed financial evaluation including TTM performance normalization, multiple valuation approaches, LBO modeling, and risk assessment through Monte Carlo simulation and scenario analysis.

Key Financial Metrics (TTM 2024-Q3 ightarrow 2025-Q2)

• TTM Revenue: \$8.75M

Adjusted EBITDA: \$1.81M (20.6% margin)

Base Case Valuation (8.5x): \$15.35M EV / \$13.32M Equity

• EPV Intrinsic Value: \$9.13M EV / \$7.10M Equity

• LBO Returns: 22.8% IRR / 2.8x MoIC

Analysis Date: July 26, 2025

Generated by CPP Visual Report Kit

EBITDA Bridge Analysis

Adjusted EBITDA:

TTM normalization waterfall showing path from reported to adjusted EBITDA

AuroraSkin & Laser (Miami) EBITDA Bridge - 2024-Q3 → 2025-Q2 \$2.10M \$1.80M \$1.20M \$1.61M \$600K \$300K Owner Add-back Rent Normalization Reported EBITDA Adjusted EBITDA Bridge Components Margin Analysis \$8.75M Reported EBITDA: \$1.61M TTM Revenue: 18.4% \$200K Reported Margin: Owner Add-back: \$80.0K Adjusted Margin: 20.6% One-time Items: Rent Normalization:

\$1.81M

Valuation Matrix

Enterprise and equity values across multiple scenarios (7.0x - 10.0x)

AuroraSkin & Laser (Miami)


Valuation Matrix - 2024-Q3 → 2025-Q2

Multiple Enterprise Value	Equity to Seller	EV/Revenue
7.0× \$12.64M	\$10.61M	1.4×
7.5 × \$13.54M	\$11.52M	1.6×
8.0× \$14.45M	\$12.42M	1.6×
8.5× \$15.35M	\$13.32M	1.8×
9.0× \$16.25M	\$14.22M	1.9×
9.5× \$17.16M	\$15.13M	2.0×
10.0x \$18.06M	\$16.03M	2.1×

٧	aluation Summary			
٧	aluation Range:	\$10.61M - \$16.03M	Multiple Range:	7.0× - 10.0×
Е	ase Case EV:	\$15.35M	Revenue Multiple:	1.8×
Е	ase Case Equity:	\$13.32M	EBITDA Margin:	20.6%

Earnings Power Value Analysis


Intrinsic value calculation with WACC and reinvestment sensitivity



EPV provides conservative valuation floor based on normalized earnings power

LBO Analysis Summary

Sources & uses, debt schedule, and projected returns analysis



Key Performance Indicators

Operational metrics with performance benchmarks and targets

Key Performance Indicators TTM: 2024-Q3 → 2025-Q2 Revenue & Growth **Investment Returns** 3 Nin 1111/1/12 12 2 2 1 0.0% Revenue Growth EBITDA Margin MOIC Sponsor IRR Financial Health Valuation Metrics 6.2× 60% 2.0× 8.5× **41**% 13.32M Interest Coverage Debt/EBITDA Cash Conversion EV/EBITDA EPV Discount Equity Value

Monte Carlo Simulation


10,000-iteration risk analysis with statistical distributions

Monte Carlo Simulation

10,000 Scenario Analysis • 2024-Q3 \Rightarrow 2025-Q2







Scenario Analysis

Base, downside, and upside case modeling with equity impact

Scenario Analysis

Base / Downside / Upside + 2024-Q3 ightarrow 2025-Q2

Key Metrics Comparison					
Metric	Downside	Base Case	Upside	Range	
Revenue CAGR	5.0%	8.0%	11.0%	6.0%	
Year 5 Revenue	11.17M	12.86M	14.74M	3.58M	
Year 5 EBITDA Margin	20.6%	23.1%	25.6%	5.0%	
Year 5 EBITDA	2.30M	2.98M	3.78M	1.48M	
Exit Multiple	6.5×	8.0×	9.5×	3.0×	
Exit EV	14.98M	23.80M	35.91M	20.93M	
Exit Equity	5.52M	14.34M	26.45M	20.93M	
MOIC	1.3×	3.4×	6.3×	5.0×	
IRR	5.5%	27.7%	44.3%	38.8%	

	Revenue Trajectory
15.00N	1
12.00N	1
9.001	1

40% -			R	eturns Com	parison	
	(%)	40% -				

Sensitivity Analysis

IRR impact ranking of key value drivers

